Financial Tearsheet

Company Overview

Tenax Therapeutics Inc (NASDAQ:TENX)

Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions.

Recent Financial News

Date	Headline
May 16, 2017	Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission
Apr 05, 2017	Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update
Mar 21, 2017	Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update
Mar 15, 2017	Tenax Therapeutics to Discuss Year-End 2016 Financial Results and Provide Business Update
Jan 31, 2017	Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery

Stock Performance

Today's Open	0.5700
Volume	10,502
Day Range	0.5700 - 0.5948
52 Week Range	0.4140 - 2.7700
Bid/Ask	0.5700 / 0.5955
Bid/Ask Size	5,000 X 5,000
Previous Close	0.5810
Market Cap	16.34 million
Shares Outstanding	28.12 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	0.530103
P/E Ratio (TTM)	1.0960

Recent XBRL Filings

Filing Date	Form Type	Description	View
May 10, 2017	10-Q	Quarterly report	html pdf xbrl
Mar 16, 2017	10-K	Annual report	html pdf xbrl
Nov 09, 2016	10-Q	Quarterly report	html pdf xbrl
Aug 09, 2016	10-Q	Quarterly report	html pdf xbrl
May 10, 2016	10-Q	Quarterly report	html pdf xbrl

Management Team

Michael B. Jebsen, Interim CEO, Chief Financial Officer

Douglas Hay, PhD, EVP of Regulatory Affairs

Nancy Hecox, EVP, Legal Affairs, General Counsel, and Corporate Secretary

Doug Randall, EVP of Commercial and Business Operations

Board of Directors

Dr. Ronald Blanck, Chairman

John Kelley, Chief Executive Officer

Anthony DiTonno, Director

James Mitchum, Director

Gregory Pepin, Director

Gerald Proehl, Director

Chris A. Rallis, Director